DIGOXIN INJECTION C.S.D. LIQUID

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

DIGOXIN

थमां उपलब्ध:

SANDOZ CANADA INCORPORATED

ए.टी.सी कोड:

C01AA05

INN (इंटरनेशनल नाम):

DIGOXIN

डोज़:

0.5MG

फार्मास्यूटिकल फॉर्म:

LIQUID

रचना:

DIGOXIN 0.5MG

प्रशासन का मार्ग:

INTRAMUSCULAR

पैकेज में यूनिट:

10X2ML

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

CARDIOTONIC AGENTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0107281002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2005-10-05

उत्पाद विशेषताएं

                                <
D
IGOXIN INJECTION
C.S.D.
>
Page 1 of 42
Product Monograph
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DIGOXIN INJECTION C.S.D.
Digoxin Injection
Liquid, 0.5 mg / 2 mL, Intramuscular, Intravenous
Manufacturer’s Standard
Cardiotonic Glycoside
Sandoz Canada Inc.
110 rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Date of Initial Authorization:
DEC 31, 1994
Date of Revision:
SEP 14, 2022
Submission Control Number: 262879
_ _
_ _
Page 2 of 42
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics (<10 years of age)
................................................................................
4
1.2
Geriatrics (>70 years of age)
................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................... 5
4.4
Administration
...................................................................................................
10
4.5
Missed Dose
..........................................................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 14-09-2022

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें